Pulse Biosciences (PLSE) EBIT (2015 - 2026)

Pulse Biosciences has reported EBIT for 12 years, with the latest figure at -$25.3 million in Q2 2026.

• On a quarterly basis, EBIT fell 24.65% year-over-year to -$25.3 million in Q2 2026; TTM through Jun 2026 was -$84.2 million, a 16.52% decrease from a year earlier, with the FY2025 full-year figure at -$76.9 million, down 36.76% from the prior year.
• EBIT was -$25.3 million for Q2 2026 at Pulse Biosciences, down from -$18.3 million in the prior quarter.
• The five-year high for EBIT was -$8.7 million in Q4 2022, with the low at -$25.3 million in Q2 2026.
• Average EBIT over 5 years is -$15.3 million, with a median of -$14.0 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: EBIT soared 44.64% in 2023, then slumped 72.91% in 2025.
• Over 5 years, EBIT stood at -$8.7 million in 2022, then tumbled by 43.32% to -$12.5 million in 2023, then plunged by 61.66% to -$20.3 million in 2024, then climbed by 9.91% to -$18.3 million in 2025, then sank by 38.45% to -$25.3 million in 2026.
• The last three EBIT figures came in at -$25.3 million (Q2 2026), -$18.3 million (Q4 2025), and -$20.4 million (Q3 2025), per Business Quant data.